NICE recommends use of Mylotarg in CD33-positive acute myeloid leukaemia.- Pfizer.
The National Institute for health and care excellence (NICE) has recommended Mylotarg (gemtuzumab ozogamicin), from Pfizer, for previously untreated, de novo, CD33-positive acute myeloid leukaemia in combination with chemotherapy. The Final Appraisal Determination backs use of the drug in combination with daunorubicin and cytarabine for untreated CD33-positive AML (except acute promyelocytic leukaemia) in people 15 years and over with favourable, intermediate or unknown cytogenetics (because the test was unsuccessful).
In earlier draft guidance, NICE only recommended Mylotarg for patients with favourable or unknown cytogenetics. However it did not recommend it for those with intermediate cytogenetics, accounting for around 65 percent of the eligible patient population.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins